Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
CF Industries appoints Julie Scheck Freigang as chief information officer » 17:14
10/19/20
10/19
17:14
10/19/20
17:14
CF

CF Industries

$28.88 /

-0.41 (-1.40%)

, FELE

Franklin Electric

$62.33 /

-1.53 (-2.40%)

CF Industries (CF)…

CF Industries (CF) announced that Julie Scheck Freigang has joined the company as VP and chief information officer. She will be responsible for the company's global technology strategy, information technology operations and cybersecurity. Prior to joining CF, Freigang was VP, chief information officer at Franklin Electric (FELE).

ShowHide Related Items >><<
FELE Franklin Electric
$62.33 /

-1.53 (-2.40%)

CF CF Industries
$28.88 /

-0.41 (-1.40%)

10/14/20 RBC Capital
CF Industries price target lowered to $32 from $38 at RBC Capital
09/17/20
Fly Intel: Top five analyst downgrades
09/17/20 HSBC
CF Industries downgraded to Hold from Buy at HSBC
09/15/20 Susquehanna
Deteriorating crop conditions positive for fertilizers, says Susquehanna
FELE Franklin Electric
$62.33 /

-1.53 (-2.40%)

09/29/20 Baird
Franklin Electric upgraded to Outperform at Baird
09/29/20 Baird
Franklin Electric upgraded to Outperform from Neutral at Baird
07/02/20
Fly Intel: Top five analyst downgrades
07/02/20 DA Davidson
Franklin Electric downgraded to Neutral from Buy at DA Davidson
FELE Franklin Electric
$62.33 /

-1.53 (-2.40%)

CF CF Industries
$28.88 /

-0.41 (-1.40%)

CF CF Industries
$28.88 /

-0.41 (-1.40%)

CF CF Industries
$28.88 /

-0.41 (-1.40%)

CF CF Industries
$28.88 /

-0.41 (-1.40%)

Upgrade
Fly Intel: Top five analyst upgrades » 09:52
10/19/20
10/19
09:52
10/19/20
09:52
BMY

Bristol-Myers

$62.12 /

+0.86 (+1.40%)

, BAM

Brookfield

$34.21 /

+0.48 (+1.42%)

, ADM

Archer Daniels

$50.95 /

+1.15 (+2.31%)

, FN

Fabrinet

$64.59 /

+1.45 (+2.30%)

, ORLY

O'Reilly Automotive

$472.31 /

+5.45 (+1.17%)

Catch up on today's…

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) upgraded to Buy from Neutral at Guggenheim with analyst Seamus Fernandez saying he thinks Opdivo data suggest growth of the immuno-oncology franchise can return in 2021 and accelerate in 2022. 2. Brookfield (BAM) upgraded to Buy from Neutral at Citi with analyst William Katz saying the merits of the American Equity (AEL) equity stake "alters the somewhat stale narrative and opens up an incremental growth path." 3. Archer Daniels (ADM) upgraded to Overweight from Neutral at JPMorgan with analyst Thomas Simonitsch saying he expects the company's multiple to "re-rate" exiting 2020 given "resilient" Nutrition growth through the pandemic and greater confidence in the segment's growth trajectory for 2021 and beyond. 4. Fabrinet (FN) upgraded to Outperform from Market Perform at Northland with analyst Tim Savageaux saying he sees the 15% pullback in the shares being most likely driven by Huawei and Ciena (CIEN) concerns. 5. O'Reilly Automotive (ORLY) upgraded to Outperform from Market Perform at Raymond James with analyst Matthew McClintock saying he has historically been hesitant to recommend owning the stock due to valuation concerns but says the current valuation is actually attractive for a long-term financial algorithm that has many reasons to accelerate relative to recent years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
ORLY O'Reilly Automotive
$472.31 /

+5.45 (+1.17%)

FN Fabrinet
$64.59 /

+1.45 (+2.30%)

BMY Bristol-Myers
$62.12 /

+0.86 (+1.40%)

BAM Brookfield
$34.21 /

+0.48 (+1.42%)

ADM Archer Daniels
$50.95 /

+1.15 (+2.31%)

BMY Bristol-Myers
$62.12 /

+0.86 (+1.40%)

10/19/20 Guggenheim
Bristol-Myers upgraded to Buy after positive Opdivo data at Guggenheim
10/19/20 Guggenheim
Bristol-Myers upgraded to Buy from Neutral at Guggenheim
10/16/20 JPMorgan
Bristol-Myers price target raised to $78 from $74 at JPMorgan
10/08/20 Piper Sandler
Piper cuts Cytokinetics target to $25, but buyer on weakness after trial data
BAM Brookfield
$34.21 /

+0.48 (+1.42%)

10/19/20 Citi
Brookfield upgraded to Buy from Neutral at Citi
09/23/20 JPMorgan
Brookfield shares remain undervalued, says JPMorgan
08/17/20 Keefe Bruyette
Brookfield upgraded to Outperform from Market Perform at Keefe Bruyette
06/08/20 JPMorgan
Brookfield initiated with an Overweight at JPMorgan
ADM Archer Daniels
$50.95 /

+1.15 (+2.31%)

10/19/20 JPMorgan
Archer Daniels upgraded to Overweight with $60 target at JPMorgan
10/19/20 JPMorgan
Archer Daniels upgraded to Overweight from Neutral at JPMorgan
08/13/20 Baird
Archer Daniels named a Fresh Pick at Baird
07/28/20 Seaport Global
Archer Daniels initiated with a Buy at Seaport Global
FN Fabrinet
$64.59 /

+1.45 (+2.30%)

10/19/20 Northland
Fabrinet upgraded to Outperform following pullback at Northland
10/19/20 Northland
Fabrinet upgraded to Outperform from Market Perform at Northland
08/18/20 Needham
Fabrinet price target raised to $85 from $81 at Needham
08/18/20 B. Riley Securities
Fabrinet price target raised to $67 from $59 at B. Riley FBR
ORLY O'Reilly Automotive
$472.31 /

+5.45 (+1.17%)

10/19/20 Raymond James
O'Reilly Automotive upgraded to Outperform from Market Perform at Raymond James
10/19/20 Raymond James
O'Reilly Automotive upgraded to Outperform from Market Perform at Raymond James
10/05/20 Exane BNP Paribas
O'Reilly Automotive initiated with an Outperform at Exane BNP Paribas
09/23/20 RBC Capital
AutoZone price target raised to $1,329 from $1,323 at RBC Capital
ORLY O'Reilly Automotive
$472.31 /

+5.45 (+1.17%)

FN Fabrinet
$64.59 /

+1.45 (+2.30%)

BMY Bristol-Myers
$62.12 /

+0.86 (+1.40%)

BAM Brookfield
$34.21 /

+0.48 (+1.42%)

ADM Archer Daniels
$50.95 /

+1.15 (+2.31%)

BMY Bristol-Myers
$62.12 /

+0.86 (+1.40%)

BAM Brookfield
$34.21 /

+0.48 (+1.42%)

ADM Archer Daniels
$50.95 /

+1.15 (+2.31%)

ORLY O'Reilly Automotive
$472.31 /

+5.45 (+1.17%)

FN Fabrinet
$64.59 /

+1.45 (+2.30%)

BMY Bristol-Myers
$62.12 /

+0.86 (+1.40%)

BAM Brookfield
$34.21 /

+0.48 (+1.42%)

ADM Archer Daniels
$50.95 /

+1.15 (+2.31%)

FN Fabrinet
$64.59 /

+1.45 (+2.30%)

BMY Bristol-Myers
$62.12 /

+0.86 (+1.40%)

ADM Archer Daniels
$50.95 /

+1.15 (+2.31%)

Recommendations
Bunge price target raised to $61 from $47 at JPMorgan » 07:58
10/19/20
10/19
07:58
10/19/20
07:58
BG

Bunge

$54.62 /

+0.4 (+0.74%)

JPMorgan analyst Thomas…

JPMorgan analyst Thomas Simonitsch raised the firm's price target on Bunge to $61 from $47 and keeps a Neutral rating on the shares. The near term fundamental outlook for Bunge's core business is much improved from the Q2 results, led by accelerated China purchases of U.S. agriculture products and a superior soy crush margin environment that should translate into "solid" Q3 results next week, Simonitsch tells investors in a research note.

ShowHide Related Items >><<
BG Bunge
$54.62 /

+0.4 (+0.74%)

BG Bunge
$54.62 /

+0.4 (+0.74%)

08/14/20 Credit Suisse
Bunge price target raised to $53 from $50 at Credit Suisse
08/13/20 Baird
Bunge named a Fresh Pick at Baird
07/27/20 Credit Suisse
Bunge price target lowered to $50 from $65 at Credit Suisse
06/25/20 Stephens
Bunge named a Best Idea at Stephens
BG Bunge
$54.62 /

+0.4 (+0.74%)

BG Bunge
$54.62 /

+0.4 (+0.74%)

BG Bunge
$54.62 /

+0.4 (+0.74%)

Upgrade
Archer Daniels upgraded to Overweight with $60 target at JPMorgan » 07:57
10/19/20
10/19
07:57
10/19/20
07:57
ADM

Archer Daniels

$49.79 /

-0.15 (-0.30%)

JPMorgan analyst Thomas…

JPMorgan analyst Thomas Simonitsch upgraded Archer Daniels Midland to Overweight from Neutral with a price target of $60, up from $45. The analyst expects the company's multiple to "re-rate" exiting 2020 given "resilient" Nutrition growth through the pandemic and greater confidence in the segment's growth trajectory for 2021 and beyond. This results in less volatile earnings and cash flows for Archer Daniels, Simonitsch tells investors in a research note. Further, the near term fundamental outlook for Archer's core business is much improved from the Q2 results, led by accelerated China purchases of U.S. agriculture products and a superior soy crush margin environment that should translate into "solid" Q3 results next week, adds the analyst.

ShowHide Related Items >><<
ADM Archer Daniels
$49.79 /

-0.15 (-0.30%)

ADM Archer Daniels
$49.79 /

-0.15 (-0.30%)

10/19/20 JPMorgan
Archer Daniels upgraded to Overweight from Neutral at JPMorgan
08/13/20 Baird
Archer Daniels named a Fresh Pick at Baird
07/28/20 Seaport Global
Archer Daniels initiated with a Buy at Seaport Global
07/27/20 Credit Suisse
Archer Daniels downgraded to Underperform from Neutral at Credit Suisse
ADM Archer Daniels
$49.79 /

-0.15 (-0.30%)

ADM Archer Daniels
$49.79 /

-0.15 (-0.30%)

ADM Archer Daniels
$49.79 /

-0.15 (-0.30%)

ADM Archer Daniels
$49.79 /

-0.15 (-0.30%)

Upgrade
Archer Daniels upgraded to Overweight from Neutral at JPMorgan » 04:48
10/19/20
10/19
04:48
10/19/20
04:48
ADM

Archer Daniels

$49.79 /

-0.15 (-0.30%)

JPMorgan analyst Thomas…

JPMorgan analyst Thomas Simonitsch upgraded Archer Daniels to Overweight from Neutral with a $60 price target.

ShowHide Related Items >><<
ADM Archer Daniels
$49.79 /

-0.15 (-0.30%)

ADM Archer Daniels
$49.79 /

-0.15 (-0.30%)

08/13/20 Baird
Archer Daniels named a Fresh Pick at Baird
07/28/20 Seaport Global
Archer Daniels initiated with a Buy at Seaport Global
07/27/20 Credit Suisse
Archer Daniels downgraded to Underperform from Neutral at Credit Suisse
06/30/20 Barclays
Archer Daniels initiated with an Overweight at Barclays
ADM Archer Daniels
$49.79 /

-0.15 (-0.30%)

ADM Archer Daniels
$49.79 /

-0.15 (-0.30%)

ADM Archer Daniels
$49.79 /

-0.15 (-0.30%)

ADM Archer Daniels
$49.79 /

-0.15 (-0.30%)

Over a week ago
Recommendations
CF Industries price target lowered to $32 from $38 at RBC Capital » 08:58
10/14/20
10/14
08:58
10/14/20
08:58
CF

CF Industries

$29.43 /

-0.035 (-0.12%)

RBC Capital analyst…

RBC Capital analyst Andrew Wong lowered the firm's price target on CF Industries to $32 from $38 and keeps a Sector Perform rating on the shares. The analyst is citing the headwinds of lower pricing and higher costs in the near term in noting that the upside on the stock may be limited, though he also sees some potential for nitrogen prices to stage a "moderate rebound" in the spring. CF Industries free cash flow also remains solid, Wong tells investors in a research note.

ShowHide Related Items >><<
CF CF Industries
$29.43 /

-0.035 (-0.12%)

09/17/20
Fly Intel: Top five analyst downgrades
09/17/20 HSBC
CF Industries downgraded to Hold from Buy at HSBC
09/15/20 Susquehanna
Deteriorating crop conditions positive for fertilizers, says Susquehanna
08/10/20 Citi
CF Industries upgraded to Buy from Neutral at Citi
CF CF Industries
$29.43 /

-0.035 (-0.12%)

CF CF Industries
$29.43 /

-0.035 (-0.12%)

CF CF Industries
$29.43 /

-0.035 (-0.12%)

CF CF Industries
$29.43 /

-0.035 (-0.12%)

Options
Archer Daniels call volume above normal and directionally bullish » 13:05
10/12/20
10/12
13:05
10/12/20
13:05
ADM

Archer Daniels

$49.85 /

+0.87 (+1.78%)

Bullish option flow…

Bullish option flow detected in Archer Daniels with 1,170 calls trading, 1.0x expected, and implied vol increasing over 4 points to 32.50%. Mar-21 50 calls and Mar-21 55 calls are the most active options, with total volume in those strikes near 540 contracts. The Put/Call Ratio is 0.18. Earnings are expected on October 29th.

ShowHide Related Items >><<
ADM Archer Daniels
$49.85 /

+0.87 (+1.78%)

ADM Archer Daniels
$49.85 /

+0.87 (+1.78%)

08/13/20 Baird
Archer Daniels named a Fresh Pick at Baird
07/28/20 Seaport Global
Archer Daniels initiated with a Buy at Seaport Global
07/27/20 Credit Suisse
Archer Daniels downgraded to Underperform from Neutral at Credit Suisse
06/30/20 Barclays
Archer Daniels initiated with an Overweight at Barclays
ADM Archer Daniels
$49.85 /

+0.87 (+1.78%)

ADM Archer Daniels
$49.85 /

+0.87 (+1.78%)

ADM Archer Daniels
$49.85 /

+0.87 (+1.78%)

ADM Archer Daniels
$49.85 /

+0.87 (+1.78%)

Hot Stocks
ADM, Spiber partner on production of biobased polymers » 11:01
10/05/20
10/05
11:01
10/05/20
11:01
ADM

Archer Daniels

$47.12 /

+0.39 (+0.83%)

ADM and Spiber announced…

ADM and Spiber announced an agreement to expand the production of Spiber's Brewed Protein polymers for use in apparel and other consumer products. The collaboration will combine Spiber's cutting-edge structural protein fermentation technology with ADM's deep expertise in large-scale fermentation technologies, engineering, operations and extensive agricultural supply chain. The Brewed Protein polymers will be produced by ADM in the U.S. using plant-based dextrose as a feedstock, and then shipped to Spiber downstream facilities, where they will be processed into an array of materials - primarily fibers - for use in a variety of applications such as apparel, lightweight auto parts, high-performance foams, and more. Brewed Protein polymers will play a critical role in expanding the range of plant-based, sustainable alternative materials.

ShowHide Related Items >><<
ADM Archer Daniels
$47.12 /

+0.39 (+0.83%)

ADM Archer Daniels
$47.12 /

+0.39 (+0.83%)

08/13/20 Baird
Archer Daniels named a Fresh Pick at Baird
07/28/20 Seaport Global
Archer Daniels initiated with a Buy at Seaport Global
07/27/20 Credit Suisse
Archer Daniels downgraded to Underperform from Neutral at Credit Suisse
06/30/20 Barclays
Archer Daniels initiated with an Overweight at Barclays
ADM Archer Daniels
$47.12 /

+0.39 (+0.83%)

ADM Archer Daniels
$47.12 /

+0.39 (+0.83%)

ADM Archer Daniels
$47.12 /

+0.39 (+0.83%)

ADM Archer Daniels
$47.12 /

+0.39 (+0.83%)

Options
Largest borrow rate increases among liquid names » 08:45
09/28/20
09/28
08:45
09/28/20
08:45
TAN

Claymore/MAC Global Solar Energy Index

$57.64 /

+1.86 (+3.33%)

, VBIV

VBI Vaccines

$3.07 /

+0.16 (+5.50%)

, CRBP

Corbus Pharmaceuticals

$1.56 /

+0.03 (+1.96%)

, AXU

Alexco Resource

$2.59 /

-0.105 (-3.90%)

, FIZZ

National Beverage

$70.06 /

+0.23 (+0.33%)

, CF

CF Industries

$30.42 /

-0.27 (-0.88%)

, PSTI

Pluristem

$9.66 /

+0.79 (+8.91%)

, MAXR

Maxar Technologies

$24.20 /

+0.515 (+2.17%)

, ADMA

ADMA Biologics

$2.18 /

+0.135 (+6.60%)

, XERS

Xeris Pharmaceuticals

$5.75 /

+0.19 (+3.42%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Guggenheim Global Solar Index (TAN) 8.88% +3.12, VBI Vaccines (VBIV) 18.89% +2.79, Corbus Pharmaceuticals (CRBP) 85.32% +0.95, Alexco Resource (AXU) 36.23% +0.66, National Beverage (FIZZ) 1.52% +0.41, CF Industries (CF) 0.49% +0.24, Pluristem (PSTI) 40.37% +0.22, Maxar Technologies (MAXR) 0.53% +0.18, Adma Biologics (ADMA) 2.20% +0.16, and Xeris Pharmaceuticals (XERS) 47.80% +0.16.

ShowHide Related Items >><<
XERS Xeris Pharmaceuticals
$5.75 /

+0.19 (+3.42%)

VBIV VBI Vaccines
$3.07 /

+0.16 (+5.50%)

PSTI Pluristem
$9.66 /

+0.79 (+8.91%)

MAXR Maxar Technologies
$24.20 /

+0.515 (+2.17%)

CRBP Corbus Pharmaceuticals
$1.56 /

+0.03 (+1.96%)

AXU Alexco Resource
$2.59 /

-0.105 (-3.90%)

ADMA ADMA Biologics
$2.18 /

+0.135 (+6.60%)

TAN Claymore/MAC Global Solar Energy Index
$57.64 /

+1.86 (+3.33%)

VBIV VBI Vaccines
$3.07 /

+0.16 (+5.50%)

08/27/20 Raymond James
VBI Vaccines upgraded to Strong Buy from Outperform at Raymond James
08/27/20 Oppenheimer
VBI Vaccines' COVID vaccine has potential to be best-in-class, says Oppenheimer
08/26/20 Raymond James
VBI Vaccines upgraded to Strong Buy from Outperform at Raymond James
06/23/20 Oppenheimer
VBI Vaccines price target raised to $8 from $5 at Oppenheimer
CRBP Corbus Pharmaceuticals
$1.56 /

+0.03 (+1.96%)

09/08/20 Jefferies
Corbus Pharmaceuticals downgraded to Hold from Buy at Jefferies
09/08/20 Oppenheimer
Corbus Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
09/08/20 Jefferies
Corbus Pharmaceuticals downgraded to Hold from Buy at Jefferies
09/08/20 RBC Capital
Corbus Pharmaceuticals downgraded at RBC Capital after RESOLVE-1 study data
AXU Alexco Resource
$2.59 /

-0.105 (-3.90%)

FIZZ National Beverage
$70.06 /

+0.23 (+0.33%)

05/18/20 Guggenheim
National Beverage price target raised to $38 from $34 at Guggenheim
11/18/19 Guggenheim
Coca-Cola's 'AHA' likely to take shelf space from LaCroix, says Guggenheim
11/11/19 Jefferies
National Beverage estimates and price target lowered at Jefferies
CF CF Industries
$30.42 /

-0.27 (-0.88%)

09/17/20
Fly Intel: Top five analyst downgrades
09/17/20 HSBC
CF Industries downgraded to Hold from Buy at HSBC
09/15/20 Susquehanna
Deteriorating crop conditions positive for fertilizers, says Susquehanna
08/10/20 Citi
CF Industries upgraded to Buy from Neutral at Citi
PSTI Pluristem
$9.66 /

+0.79 (+8.91%)

07/24/20 Jefferies
Pluristem price target raised to $16 from $12 at Jefferies
06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
06/19/20 Jefferies
Pluristem initiated with a Buy at Jefferies
04/24/20 H.C. Wainwright
Pluristem removed overhang with loan agreement, says H.C. Wainwright
MAXR Maxar Technologies
$24.20 /

+0.515 (+2.17%)

08/06/20 TD Securities
Maxar Technologies upgraded to Buy from Speculative Buy at TD Securities
06/24/20 JPMorgan
Maxar Technologies price target raised to $20 from $16 at JPMorgan
01/15/20 Credit Suisse
Maxar Technologies upgraded to Neutral from Underperform at Credit Suisse
01/08/20 JPMorgan
Maxar Technologies price target raised to $25 from $15 at JPMorgan
ADMA ADMA Biologics
$2.18 /

+0.135 (+6.60%)

05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
03/16/20 H.C. Wainwright
ADMA Biologics price target lowered to $12 from $14 at H.C. Wainwright
XERS Xeris Pharmaceuticals
$5.75 /

+0.19 (+3.42%)

08/20/20 Mizuho
Mizuho sees no material impact to Xeris following FDA letter about advertising
04/23/20 Mizuho
Xeris Pharmaceuticals price target lowered to $14 from $18 at Mizuho
02/20/20 Mizuho
Xeris Pharmaceuticals price target lowered to $18 from $22 at Mizuho
02/18/20
Fly Intel: Top five analyst initiations
XERS Xeris Pharmaceuticals
$5.75 /

+0.19 (+3.42%)

MAXR Maxar Technologies
$24.20 /

+0.515 (+2.17%)

FIZZ National Beverage
$70.06 /

+0.23 (+0.33%)

CRBP Corbus Pharmaceuticals
$1.56 /

+0.03 (+1.96%)

CF CF Industries
$30.42 /

-0.27 (-0.88%)

ADMA ADMA Biologics
$2.18 /

+0.135 (+6.60%)

  • 26
    Jun
  • 22
    Apr
  • 25
    Mar
  • 12
    Feb
  • 07
    Feb
  • 07
    Feb
VBIV VBI Vaccines
$3.07 /

+0.16 (+5.50%)

FIZZ National Beverage
$70.06 /

+0.23 (+0.33%)

CF CF Industries
$30.42 /

-0.27 (-0.88%)

XERS Xeris Pharmaceuticals
$5.75 /

+0.19 (+3.42%)

VBIV VBI Vaccines
$3.07 /

+0.16 (+5.50%)

PSTI Pluristem
$9.66 /

+0.79 (+8.91%)

MAXR Maxar Technologies
$24.20 /

+0.515 (+2.17%)

FIZZ National Beverage
$70.06 /

+0.23 (+0.33%)

CRBP Corbus Pharmaceuticals
$1.56 /

+0.03 (+1.96%)

CF CF Industries
$30.42 /

-0.27 (-0.88%)

ADMA ADMA Biologics
$2.18 /

+0.135 (+6.60%)

XERS Xeris Pharmaceuticals
$5.75 /

+0.19 (+3.42%)

VBIV VBI Vaccines
$3.07 /

+0.16 (+5.50%)

TAN Claymore/MAC Global Solar Energy Index
$57.64 /

+1.86 (+3.33%)

PSTI Pluristem
$9.66 /

+0.79 (+8.91%)

FIZZ National Beverage
$70.06 /

+0.23 (+0.33%)

CRBP Corbus Pharmaceuticals
$1.56 /

+0.03 (+1.96%)

CF CF Industries
$30.42 /

-0.27 (-0.88%)

AXU Alexco Resource
$2.59 /

-0.105 (-3.90%)

ADMA ADMA Biologics
$2.18 /

+0.135 (+6.60%)

Over a month ago
Upgrade
Seaport upgrades Andersons to Buy on improving grain sector fundamentals » 06:28
09/24/20
09/24
06:28
09/24/20
06:28
ANDE

Andersons

$17.95 /

-0.69 (-3.70%)

As previously reported,…

As previously reported, Seaport Global analyst Eric Larson upgraded Andersons to Buy from Neutral with a $26 price target. Grain sector fundamentals are improving "rapidly" after six straight years of challenging conditions, said Larson, who views Andersons as in a "great position to benefit during the recovery." He sees accelerating earnings growth beginning in the second half of 2020 and believes the company can achieve its annual adjusted EBITDA goal of $300M-plus in 2021, Larson added.

ShowHide Related Items >><<
ANDE Andersons
$17.95 /

-0.69 (-3.70%)

ANDE Andersons
$17.95 /

-0.69 (-3.70%)

09/24/20 Seaport Global
Andersons upgraded to Buy from Neutral at Seaport Global
09/14/20 BMO Capital
Andersons upgraded to Outperform from Market Perform at BMO Capital
08/26/20 National Securities
Andersons initiated with a Buy at National Securities
07/28/20 Seaport Global
Andersons initiated with a Neutral at Seaport Global
ANDE Andersons
$17.95 /

-0.69 (-3.70%)

ANDE Andersons
$17.95 /

-0.69 (-3.70%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.